Related Experiment Video

Updated: May 19, 2026

A Simple and Efficient Approach to Construct Mutant Vaccinia Virus Vectors
09:16

A Simple and Efficient Approach to Construct Mutant Vaccinia Virus Vectors

Published on: October 30, 2016

Progressive vaccinia: case description and laboratory-guided therapy with vaccinia immune globulin, ST-246, and

Edith R Lederman1, Whitni Davidson, Harold L Groff

  • 1National Center for Zoonotic Vector Borne and Enteric Disease, Centers for Disease Control and Prevention, Atlanta, GA, USA. erlederman@yahoo.com

The Journal of Infectious Diseases
|August 21, 2012
PubMed

Insights

Progressive vaccinia (PV), a severe smallpox vaccine complication, was treated with novel antivirals. Despite drug resistance, the patient recovered, highlighting the need for new anti-orthopoxvirus drugs and robust clinical support.

Area of Science:

  • Immunology
  • Virology
  • Pharmacology

Background:

  • Progressive vaccinia (PV) is a rare, life-threatening condition in individuals with compromised cellular immunity post-smallpox vaccination.
  • Management of PV is challenging, often requiring extensive clinical and laboratory support.

Purpose of the Study:

  • To detail the management of a patient with progressive vaccinia.
  • To illustrate the use of investigational antiviral agents (ST-246 and CMX001) and vaccinia immune globulin in treating PV.
  • To highlight the role of molecular, pharmacokinetic, and immunologic studies in guiding therapy.

Main Methods:

  • Case report of a patient with progressive vaccinia.
  • Treatment involved vaccinia immune globulin, ST-246, and CMX001.
  • Therapeutic adjustments were guided by molecular, pharmacokinetic, and immunologic monitoring.

Main Results:

  • The patient experienced resolution of progressive vaccinia despite developing resistance to ST-246.
  • Intensive clinical and laboratory support was crucial for successful management.
  • The case underscores the utility of investigational antivirals in severe orthopoxvirus infections.

Conclusions:

  • Novel anti-orthopoxvirus pharmaceuticals are essential for managing severe vaccinia infections.
  • Timely and intensive clinical and laboratory support is critical for effective PV treatment.
  • This case demonstrates successful PV management with investigational agents, even with emergent drug resistance.

More Related Videos

Vaccinia Reporter Viruses for Quantifying Viral Function at All Stages of Gene Expression10:48

Vaccinia Reporter Viruses for Quantifying Viral Function at All Stages of Gene Expression

Published on: May 15, 2014

Rapid, Seamless Generation of Recombinant Poxviruses using Host Range and Visual Selection09:25

Rapid, Seamless Generation of Recombinant Poxviruses using Host Range and Visual Selection

Published on: May 24, 2020

Related Concept Videos

Cytomegalovirus Disease01:27

Cytomegalovirus Disease

Cytomegalovirus (CMV) disease is caused by human cytomegalovirus, a double-stranded DNA virus of the Herpesviridae family. While primary CMV infection is often asymptomatic in immunocompetent individuals, the virus can cause severe disease in neonates and immunocompromised patients. CMV is the most common cause of congenital viral infection in the United States, and a major pathogen in solid organ and hematopoietic stem cell transplant recipients.CMV is transmitted via bodily fluids, sexual...
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Vaccinations01:51

Vaccinations

Overview
Vaccine Production01:23

Vaccine Production

Vaccine production involves a sequence of upstream and downstream processes to generate a safe and effective immunological product. It begins with cultivating microorganisms, such as viruses or bacteria, to obtain antigenic material. For viral vaccines, mammalian host cells are grown in bioreactors and subsequently infected with the target virus. The virus replicates within the host cells, which are lysed to release viral particles. This lysate is then clarified through filtration or...